

Novel Method of Treatment

5 Field of the Invention

This invention relates to a novel method of treatment using amoxycillin and for novel formulations, in particular tablet formulations, for use in such methods.

Background of the Invention

10 Amoxycillin is a well known β -lactam antibiotic which has been available for many years. Despite the susceptibility of amoxycillin to inhibition by β -lactamases produced by resistant organisms, amoxycillin still enjoys widespread usage as a broad spectrum antibiotic for the treatment of commonly occurring bacterial infections. In particular, amoxycillin is particularly effective in treating
15 sore throats – acute bacterial tonsillitis and/or pharyngitis where the causative organism is almost exclusively *Streptococcus pyogenes*.

Amoxycillin is available commercially in a variety of formulations, for instance as capsules containing either 250 or 500 mg amoxycillin, as tablets comprising 500 or 875 mg amoxycillin, as chewable tablets comprising either 125 or
20 250 mg amoxycillin and as dry powder formulation, for reconstitution into an oral suspension. Other formulation types include dispersible tablets providing 500 mg amoxycillin, chewable effervescent tablets, comprising 125, 250 or 500 mg amoxycillin and single dose sachets comprising 750 or 3000 mg amoxycillin. The standard adult dosage is 250 mg. three times daily (tid), increasing to 500 mg tid for
25 more severe infections. In addition, the 875 mg tablet is intended for dosing twice daily (bid), as an alternative to the dosage regimen of 500 mg tid. Recently, a 1000 mg chewing tablet has been advertised as being under development (AC Pharma, see SCRIP No 2472 September 15th 1999, page 11). A high dosage of 3 g, bid, is recommended in appropriate cases for the treatment of severe or recurrent purulent
30 infection of the respiratory tract. For short course therapy, in simple urinary tract infections, two 3g doses, at an interval of 10-12 hours, are given while for a dental abscess, the dosage is two 3 g doses at an interval of 8 h and for gonorrhoea, a single dose of 3 g. Furthermore, the use of 1g of amoxycillin, bid, is used as one arm of a combination therapy, for eradication of *Helicobacter pylori* in peptic ulcer disease.

35 In addition, amoxycillin is provided in combination with the β -lactamase inhibitor potassium clavulanate. in various tablet formulations of amoxycillin and potassium clavulanate comprising various different weights and ratios of

amoxycillin and potassium clavulanate, for instance, conventional swallow tablets comprising 250/125, 500/125, 500/62.5, and 875/125 mg amoxycillin/clavulanic acid (in the form of potassium clavulanate). Such tablets comprise amoxycillin and clavulanic acid in the ratio 2:1, 4:1, 8:1 and 7:1, respectively. The 875/125 mg tablet was developed to provide a tablet formulation which could be administered in a bid (twice daily) dosage regimen. It is also marketed for tid (three times daily) dosing, in Italy and Spain. The 500/62.5 mg tablet was also developed to provide a tablet formulation which could be administered in a bid dosage regimen, two such tablets being taken every 12h, in preference to a single 1000/125 mg tablet. A 1000/125mg single dosage is also available, in France, but as a single dosage sachet rather than a tablet. Typically, the approved regimen provides a single dosage of 125 mg of potassium clavulanate.

In addition, WO 97/09042 (SmithKline Beecham) describes tablet formulations comprising amoxycillin and clavulanic acid in a ratio in the range 12:1 to 20:1, preferably 14:1. Furthermore, it is suggested that the preferred dosage of 1750/125mg may be provided as two tablets, the first comprising 875/125mg amoxycillin and clavulanic acid and the second 875 mg amoxycillin. The 14:1 ratio is said to be useful for the empiric treatment of bacterial infection potentially caused by drug resistant *S pneumoniae* (DRSP). This patent application also describes paediatric formulations comprising amoxycillin and clavulanate in a 14:1 ratio, for administering amoxycillin dosages of 90 mg/kg/day. Data suggest that such a dosage may provide antibiotic concentrations sufficient to eradicate DRSP with amoxycillin +/- clavulanic acid MICs $\leq 4 \mu\text{g/ml}$ (Bottenfield et al, *Pediatr Infect Dis J*, 1998, 17, 963-8).

Existing marketed tablet formulations of amoxycillin are conventional in that they provide immediate release of the active ingredients once the tablet reaches the stomach. There has also been some interest in developing formulations in which the release profile is modified, to allow for a longer interval between dosages, for instances, every 12 hours (bid, q12h), rather than every 8 hours (tid, q8h).

Thus, for instance, WO 94/06416 (Jagotec AG) describes multi-layered tablets comprising 500 mg of amoxycillin distributed equally between an immediate release and a slow release layer. Furthermore, WO 95/20946 (SmithKline Beecham) describes *inter alia* a layered tablet comprising about 500 mg amoxycillin having a first layer which is an immediate release layer and a second layer which is a slow release layer, the ratio of amoxycillin between the two layers being about 1:2.6, as well as an intermediate barrier layer. Further bilayered tablets comprising clavulanic acid and amoxycillin are described in WO 98/05305 (Quadrant Holdings Ltd). In

such tablets, a first layer comprises amoxycillin and a second layer comprises clavulanate and the excipient trehalose, to stabilise the clavulanate component.

5 In addition, WO 95/28148 (SmithKline Beecham) describes *inter alia* tablet formulations comprising amoxycillin and, optionally, clavulanate having a core comprising amoxycillin coated with a release retarding agent and surrounded by an outer casing layer of amoxycillin and potassium clavulanate. The release retarding agent is an enteric coating, so that there is a immediate release of the contents of the outer core, followed by a second phase from the core which is delayed until the core reaches the intestine. Furthermore, WO 96/04908 (SmithKline Beecham) describes
10 *inter alia* tablet formulations comprising amoxycillin in a matrix, for immediate release, and granules in a delayed release form comprising amoxycillin. Such granules are coated with an enteric coating, so release is delayed until the granules reach the intestine. WO 96/04908 (SmithKline Beecham) describes *inter alia* delayed or sustained release formulations of amoxycillin formed from granules
15 which have a core comprising amoxycillin and surrounded by a layer comprising amoxycillin.

In addition, WO 94/27557 (SmithKline Beecham) describes controlled release formulations of amoxycillin and clavulanic acid prepared using a hydrophobic waxy material which is then subjected to thermal infusion.

20 Further controlled release formulations comprising amoxycillin have been described by several groups. Thus, Arancibia *et al* ((Int J of Clin Pharm, Ther and Tox, 1987, 25, 97-100) describe the pharmacokinetic properties and bioavailability of a controlled release formulation comprising 500 mg of amoxycillin. No further details of the formulation are provided. The formulation was however designed to
25 release 21 to 35% during the first 60 minutes, 51 to 66% at 4 hours, 70 to 80% at 6 hours, 81 to 90% at 8 hours and more than 94% at 12 hours. They however found little, if any, correlation between the *in vitro* dissolution rate and the pharmacokinetic behaviour in the body. Hilton *et al* (International Journal of Pharmaceutics, 1992, 86, 79-88) described an alternative controlled release tablet
30 having a hydrophilic polymer matrix and a gas release system, to provide intragastric buoyancy, to enhance gastric retention time. This showed no advantage over a conventional capsule formulation, with bioavailability being diminished. In contrast, Hilton *et al* (Journal of Pharmaceutical Sciences, 1993, 82, 737-743) described a 750 mg controlled release tablet incorporating the enteric polymer
35 hydroxypropylmethyl cellulose acetate succinate. This however failed to show any advantage over a conventional capsule. In particular, the bioavailability was reduced to 64.6% compared with the same dosage provided in a capsule. More recently,

Hoffman *et al* (Journal of Controlled Release, 1998, 54, 29-37 and WO 98/22091) have described a tablet comprising 500 mg of amoxycillin in a matrix comprising hydroxypropyl methyl cellulose, designed to release 50% of its contents in the first three hours and complete the drug release process over eight hours. The time above
5 MIC was found to be significantly extended, compared to a capsule formulation, but not enough for a 12 h dosing interval. The discussion is in the context of a theoretical MIC of 0.2 µg/ml.

Summary of the Invention

10 The present invention relates to a method of treating bacterial infections in humans which comprises administering thereto a therapeutically effective amount of amoxycillin in the range 1900 to 2600 mg, at a dosage regimen/interval of about 12 hours. Suitably, the infection is caused by the organisms *S pneumoniae* (including Drug Resistant and Penicillin Resistant *S pneumoniae*), *H influenzae M catarrhalis*
15 and/or *S Pyogenes*.

The present invention also relates to a modified release pharmaceutical formulation comprising amoxycillin in which a first part of amoxycillin are formulated with pharmaceutically acceptable excipients which allow for immediate release of the first part of amoxycillin, to form an immediate release phase, and further comprising a
20 second part of amoxycillin formulated with pharmaceutically acceptable excipients which allow for slow release of the second part of amoxycillin, to form a slow release phase.

The present invention also relates to an immediate release pharmaceutical tablet formulation comprising 1000 mg \pm 5% amoxycillin in combination with
25 pharmaceutically acceptable excipients or carriers.

The present invention also relates to an immediate release pharmaceutical formulation in the form of a single dose sachet comprising 2000, 2250 or 2500 mg \pm 5% amoxycillin, or the corresponding half quantities thereof, in combination with pharmaceutically acceptable excipients or carriers.

30 Other suitable modified or immediate release formulations are described herein in greater detail.

Brief Description of the Drawings

Figure 1 shows the structure of various types of layered tablets of the present invention, in particular the structure of substantially cylindrical compressed tablets are shown in longitudinal section. In

5 Fig 1A, shows a tablet comprising a first layer (1) and a second layer (2), without any barrier layer or coating layer.

Fig 1B, shows a tablet comprising a first layer (1), a second layer (2), and a barrier layer (3) sandwiched between the first and second layers (1) and (2).

10 Fig 1C, shows a tablet comprising a first layer (1), a second layer (2), and a barrier layer (3) located on the end face of the second layer (2).

Fig 1D, shows a tablet comprising a first layer (1), a second layer (2), a barrier layer (3) sandwiched between the first and second layers (1) and (2), and a coating layer (4) which partly covers the tablet. The dotted line shows the possibility of the coating layer (4A) covering the entire tablet.

15 Fig. 1E, shows a tablet comprising a first layer (1) a second layer (2), and a third layer (3) intermediate between the first and second layers (1) and (2). All three of these layers (1), (2) and (3) include active material content.

Figure 2 demonstrates the dissolution profile for tablets of Examples 1 and 2.

Figure 3 demonstrate the pharmacokinetic profiles of Study A

20 Figure 4 demonstrates the pharmacokinetic profile for amoxycillin plasma concentration for Study B (in which A is formulation V, B is formulation VI, D is formulation VIII).

Detailed Description of the Invention

25 Part of the challenge in providing formulations of amoxycillin in which the drug release is effectively modified (and a ready explanation for the lack of success in the studies already referenced) is the relatively narrow window for absorption of the drug in the small intestine and the relatively short half life of the drug. Furthermore, the rapid elimination of amoxycillin (excretion half-life is 1.3 hours)
30 makes it difficult to maintain serum levels as clearance from the body is very rapid.

In existing tablet formulations comprising amoxycillin, amoxycillin is present in the form amoxycillin trihydrate, as the use of this form provides tablets with greater storage stability than those in which amoxycillin is present as sodium amoxycillin (see GB 2 005 538, Beecham Group Ltd). Sodium amoxycillin is
35 however used as the amoxycillin component in existing formulations of amoxycillin and potassium clavulanate adapted for IV administration. The form of sodium amoxycillin used is a spray-dried form. In addition, EP 0 131 147-A1 (Beecham

Group plc) describes a further form of sodium amoxycillin, so-called "crystalline sodium amoxycillin". A further process for preparing crystalline salts of amoxycillin, including sodium amoxycillin, is described in WO 99/62910 (SmithKline Beecham). Sodium amoxycillin is relatively water soluble in comparison to amoxycillin trihydrate.

Formulations comprising clavulanic acid and a pharmaceutically acceptable organic acid or a salt-like derivative thereof, for example calcium citrate, have been described in WO 96/07408 (SmithKline Beecham). In such formulations, it is postulated that the presence of the calcium citrate would help suppress the gastrointestinal intolerance associated with oral dosing of clavulanate-containing products.

Furthermore, US patent no. 5 051 262 (Elan Corp) describes the incorporation of an organic acid into a modified release formulation, to provide a microenvironment in which the locally modified pH helps to protect the active ingredient from degradation.

Of concern is the increasing resistance of pathogenic organisms, such as those found in respiratory tract infections, to anti-infective agents such as amoxycillin, in particular drug resistant *S pneumoniae*. Increased resistance to penicillin of *S pneumoniae* (due to modified penicillin binding proteins) is developing around the world and is affecting clinical outcomes (see for instance Applebaum P C, Ped Inf Dis J, 1996, 15(10), 932-9). These penicillin resistant *S pneumoniae* (PRSP) have also been termed "DRSP" as they often exhibit decreased susceptibility not only to penicillin but also to a wider range of antimicrobial classes, including macrolides, azalides, beta-lactams, sulfonamides and tetracyclines. Amoxycillin, along with some of the newer quinolones, has remained among the most active oral drugs against the increasingly resistant isolates of *S pneumoniae*, based on both MIC levels and pharmacokinetic properties of these compounds. Resistance rates (and MICs) have however continued to increase. Penicillin resistance in *S. pneumoniae* can be assessed according to criteria developed by the National Committee for Clinical Laboratory Standards (NCCLS), as follows: susceptible strains have MICs of ≤ 0.06 $\mu\text{g/ml}$, intermediate resistance is defined as an MIC in the range 0.12 to 1.0 $\mu\text{g/ml}$ while penicillin resistance is defined as an MIC of ≥ 2 $\mu\text{g/ml}$. Furthermore, it is found that some 10% of pneumococci now have an amoxycillin MIC of 2 $\mu\text{g/ml}$.

There is consequently a need to provide new formulations of amoxycillin that combine the known safety profile and broad spectrum with improved activity against DRSP, including PRSP, with higher MICs in empiric treatment of respiratory

infections where *S pneumoniae*, *H influenzae* and *M catarrhalis* are likely pathogens, as well as *S pyogenes*.

For β -lactams, including amoxycillin, it is recognised that the time above minimum inhibitory concentration ($T > MIC$) is the pharmacodynamic parameter most closely related to efficacy. For a variety of β -lactams, a bacteriological cure rate of 85 to 100% is achieved when serum concentrations exceed the MIC for more than about 40% of the dosing interval (Craig and Andes, *Ped Inf Dis J*, 1996, 15, 255-259). For a 12 hour dosing interval, this is about 4.8 hours.

A further parameter which may be of importance is the ratio of the maximum plasma concentration (C_{max}) to the MIC value, as this may be related to the potential to select for resistance. Too low a ratio may encourage the development of resistant strains. Preferably, the plasma C_{max} value is well above the MIC value, for instance, at least two times, more preferably at least three times, most preferably at least four times, the MIC value.

In a clinical study of an Amoxil 875 mg tablet (SmithKline Beecham), the mean amoxycillin pharmacokinetic parameters were shown to be: $AUC_{0-\infty} = 35.4 \pm 8.1 \mu g \cdot hr/mL$; $C_{max} = 13.8 \pm 4.1 \mu g \cdot hr/mL$ (Physicians Desk Reference, Medical Economics Co, 52 edition, 1998, 2802). The time above MIC was about 40% of the 12 hour dosing interval for an MIC of 2 $\mu g/ml$ and about 30% for an MIC of 4 $\mu g/ml$ (SmithKline Beecham data).

Based on the foregoing considerations, there is a continuing need to provide new dosage regimens for amoxycillin giving optimised pharmacokinetic profiles for amoxycillin, so that therapy is maximised, particularly against more resistant bacteria while the (further) development of resistance is minimised. It has now been found that such can be achieved using higher dosages of amoxycillin than previously contemplated.

Accordingly, in a first aspect, the present invention provides for a method of treating bacterial infections in humans which comprises orally administering thereto a therapeutically effective amount of amoxycillin in the range 1900 to 2600 mg, preferably 1950 to 2550 mg, at intervals of about 12 h.

Preferably, the dosage regimen provides a mean plasma concentration of amoxycillin of 4 $\mu g/mL$ for at least 4.4 h, preferably at least 4.6 h, more preferably at least 4.8 h, most preferably for about 6 h or longer.

More preferably, the dosage regimen provides a mean plasma concentration of amoxycillin of 8 $\mu g/ml$ for at least 4.4 h, more preferably at least 4.6 h, most preferably at least 4.8 h.

Preferably, the dosage regimen provides a mean maximum plasma concentration (C_{\max}) of amoxycillin which is at least 8 $\mu\text{g/mL}$, preferably at least 12 $\mu\text{g/mL}$, yet more preferably at least 14 $\mu\text{g/mL}$, most preferably at least 16 $\mu\text{g/mL}$.

5 Preferably, the mean plasma concentration of amoxycillin and the mean maximum plasma concentration of amoxycillin are measured after oral administration of a formulation comprising amoxycillin at the start of a light meal.

In a further aspect, the present invention provides for a method of treating bacterial infections in humans which comprises administering thereto a therapeutically effective amount of amoxycillin in the range 1400 to 1900 mg, preferably 1500 to 1900 mg, at intervals of about 12 h, such that the dosage regimen provides a mean plasma concentration of amoxycillin of 4 $\mu\text{g/mL}$ for at least 4.4 h, preferably at least 4.6 h, more preferably at least 4.8h, most preferably for about 6h or longer; more preferably, a mean plasma concentration of amoxycillin of 8 $\mu\text{g/mL}$ for at least 4.4 h, more preferably at least 4.6 h, most preferably at least 4.8 h, and a mean maximum plasma concentration (C_{\max}) of amoxycillin which is at least 8 $\mu\text{g/mL}$, preferably at least 12 $\mu\text{g/mL}$, yet more preferably at least 14 $\mu\text{g/mL}$, most preferably at least 16 $\mu\text{g/mL}$.

Bacterial infections amenable to the present invention include infections caused by the organisms *S pneumoniae* (including Drug Resistant *S pneumoniae* (DRSP), for instance Penicillin Resistant *S pneumoniae* (PRSP)), and/or the respiratory pathogens, most notably *H influenzae* and *M catarrhalis*, such as respiratory tract infections, including community acquired pneumoniae (CAP), acute exacerbations of chronic bronchitis (AECB) and acute bacterial sinusitis (ABS), where the higher break points achievable through the improved pharmacokinetic profile will be especially advantageous compared to existing antibacterial agents. Further bacterial infections amenable to the present invention include infections caused by the organism *Streptococcus pyogenes*, for instance acute bacterial tonsillitis and/or pharyngitis. The duration of therapy will generally be between 7 and 14 days, typically 7 days for most indications but 10 days for acute bacterial sinusitis.

30 The term "amoxycillin" as used herein shall mean amoxycillin or an alkaline salt thereof, in particular amoxycillin trihydrate and (crystallised) sodium amoxycillin, without distinction and unless otherwise indicated.

Unless otherwise indicated, weights of amoxycillin refer to the equivalent weight of the corresponding free acid. In addition, it will be appreciated that in practice, weights of amoxycillin to be incorporated into a formulation will be further

adjusted, in accord with conventional practice, to take account of the potency of the amoxycillin .

In a first embodiment, a dosage of amoxycillin of from 1900 to 2600 mg may be delivered from an immediate release formulation. Accordingly, in a further
5 aspect, the present invention provides for method of treating bacterial infections in humans which comprises administering thereto a therapeutically effective amount of amoxycillin in the range 1900 to 2600, preferably 1950 to 2550 mg, at intervals of about 12 h, wherein the dosage is delivered from an immediate formulation.

As used herein, the term "immediate release" shall mean the release of the
10 majority of the active material content within a relatively short time, for example within 1 hour, preferably within 30 minutes, after oral ingestion. Examples of such immediate release formulations include conventional swallow tablets, chewable tablets, dispersible tablets, single dose sachets and capsules.

Representative dosages include 2000, 2250 and 2500mg of amoxycillin. A
15 preferred dosage is 2000mg of amoxycillin.

The dosage in an immediate release formulation may be provided as a single tablet, for instance a dispersible tablet, a chewable tablet which may also be , effervescent and/or dispersible, a single dose capsule or a single dosage sachet, comprising, for instance, 2000, 2250 or 2500 mg amoxycillin. Alternatively, the
20 dosage may be made up of a number of smaller tablets or capsules, for instance, 2, 3 or 4, which may be the same or different. Representative such smaller tablets include swallow tablets, dispersible tablets and chewable tablets which may also be effervescent and/or dispersible. Thus, for instance, a dosage of 2000 mg amoxycillin may be provided by a combination of four tablets each comprising 500 mg
25 amoxycillin or two tablets each comprising 1000mg amoxycillin. In addition, a dosage of 2250 mg amoxycillin may be provided by a combination of four tablets comprising 500 mg amoxycillin and one tablet comprising 250 mg amoxycillin or two tablets comprising 875 mg amoxycillin and one tablet comprising 500 mg amoxycillin. Furthermore, a dosage of 2500 mg amoxycillin may be provided by a
30 combination of five tablet comprising 500 mg amoxycillin. Tablets comprising 500 and 875 mg amoxycillin are already commercially available.

It will be appreciated that immediate release tablets, in particular swallow tablets or dispersible tablets, comprising 1000mg are novel. Accordingly, in a
35 further aspect, the present invention provides for an immediate release pharmaceutical tablet formulation comprising 1000 mg $\pm 5\%$ amoxycillin, in a nominal ratio of about 16:1, in combination with pharmaceutically acceptable excipients or carriers. Immediate release tablets comprising 1000mg can be readily

prepared by adapting compositions previously described for 875/125 and 1000/125 mg tablets (see for instance, WO 95/28927 and WO 98/35672, SmithKline Beecham).

5 It will also be appreciated that immediate release single dosage sachets comprising 2000mg, 2250mg or 2500mg amoxycillin, or the corresponding half quantities thereof, are novel. Accordingly, in a further aspect, the present invention provides for an immediate release pharmaceutical formulation in the form of a single dose sachet comprising 2000, 2250 or 2500 mg \pm 5% amoxycillin, or the corresponding half quantities thereof, in combination with pharmaceutically
10 acceptable excipients or carriers. Such sachets can be readily prepared by adapting compositions previously described for 875/125 and 1000/125 mg sachets of amoxycillin/potassium clavulanate (see for instance, WO 92/19277 and WO 98/35672, SmithKline Beecham).

15 It will be further appreciated that immediate release chewable tablets comprising 2000, 2250 or 2500/125 mg are novel. Accordingly, in a further aspect, the present invention provides for an immediate release pharmaceutical formulation in the form of a chewable tablet which may be effervescent and/or dispersible comprising 2000, 2250, or 2500 mg amoxycillin, or the corresponding half quantities thereof, in combination with a chewable base and, if effervescent, an
20 effervescent couple, and other pharmaceutically acceptable excipients or carriers. Such chewable tablets can be readily prepared by adapting compositions previously described for chewable tablets comprising amoxycillin (see for instance, EP-A-0 396 335, Beecham Group and WO 98/35672, SmithKline Beecham).

25 In a second embodiment, a dosage of amoxycillin of from 1900 to 2600 mg amoxycillin may be delivered from a modified release formulation. Accordingly, in a further aspect, the present invention provides for method of treating bacterial infections in humans which comprises administering thereto a therapeutically effective amount of amoxycillin in the range 1400 to 2600mg, preferably 1900 to 2600 mg, more preferably 1950 to 2550 mg, at intervals of about 12 h, in which the
30 dosage is delivered from a modified release formulation.

As used herein, the term "modified release" shall mean a release of drug substance from a pharmaceutical formulation which is at a slower rate than from an immediate release formulation such as a conventional swallow tablet or capsule and may include an immediate release portion or phase and a slow release portion or
35 phase. Modified release formulations are well known in the art, see for instance Remington: The Science and Practice of Pharmacy, Nineteenth Edn, 1995, Mack Publishing Co, Pennsylvania, USA.

Preferably, the modified release formulations of the present invention are formulated such that the release of amoxycillin is effected predominantly through the stomach and small intestine, so that absorption through the specific amoxycillin absorption site in the small intestine is maximised. Preferably, the amoxycillin release profile is made up of a contribution from an immediate release component which is then complemented and extended by an on-going contribution from a slow release component. Such formulations are preferably formulated such that the release of amoxycillin occurs predominantly within 3 hours of ingestion of the formulation.

Representative modified release dosages include 1500, 1750 and 2000mg of amoxycillin. A preferred dosage is 2000mg of amoxycillin.

The dosage in a modified release formulation may conveniently be provided as a number of swallow tablets or capsules, for instance two, three or four which may be the same or different. Thus, for instance, a dosage of 2000 mg amoxycillin may be provided by two tablets each comprising 1000mg amoxycillin, two tablets each comprising 500 mg amoxycillin and one tablet comprising 1000 mg amoxycillin or four tablets each comprising 500 mg amoxycillin. In addition, a dosage of 1750 mg amoxycillin may be provided by two tablets each comprising 875mg amoxycillin. A preferred tablet comprises 1000mg amoxycillin.

The dosage in an modified release formulation may be may also provided as a single tablet. Because of the quantities of drug substance being used, this would preferably be other than a swallow tablet, for instance a dispersible tablet or a chewable tablet which may also be effervescent and/or dispersible or a dispersible tablet. A single unit dosage may also be conveniently provided as a single dosage sachet. It will be appreciated that the dosage may also be provided as a number of smaller non-swallow tablets or sachets, for instance 2 x 1000 or 4 x 500mg amoxycillin.

Preferably, in the modified release formulation, the amoxycillin is provided in both an immediate release and a slow release phase.

Accordingly, in a further aspect, the present invention provides for a modified release pharmaceutical formulation comprising amoxycillin in which a first part of amoxycillin is formulated with pharmaceutically acceptable excipients which allow for immediate release of the first part of amoxycillin, to form an immediate release phase, and further comprising a second part of amoxycillin formulated with pharmaceutically acceptable excipients which allow for slow release of the second part of amoxycillin, to form a slow release phase.

As used herein, the term "slow release" shall mean the gradual, but continuous or sustained release, over a relatively extended period of the active

material content (in this case amoxycillin) after oral ingestion and which starts when the formulation reaches the stomach and starts to disintegrate/dissolve. The release will continue over a period of time and may continue through until and after the formulation reaches the intestine. This can be contrasted with the term "delayed release" in which release of the active does not start immediately the formulation reaches the stomach but is delayed for a period of time, for instance until when the formulation reaches the intestine when the increasing pH is used to trigger release of the active from the formulation.

Preferably, the modified release formulation has an *in vitro* dissolution profile in which 45 to 65%, preferably 45 to 55% of the amoxycillin content is dissolved within 30 min; further in which 50 to 75%, preferably 55 to 65% of the amoxycillin content is dissolved within 60 min; further in which 55 to 85%, preferably 60 to 70% of the amoxycillin content is dissolved within 120 min; further in which 70 to 95%, preferably 75 to 85% of the amoxycillin content is dissolved within 180 min; and further in which 70 to 100%, preferably 75 to 100% of the amoxycillin content is dissolved within 240 min. In comparison, a conventional, immediate release amoxycillin tablet dissolves essentially completely within 30 minutes. The dissolution profile may be measured in a standard dissolution assay, for instance <711> Dissolution Test, Apparatus 2, provided in USP 23, 1995, at 37.0 ± 0.5°C, using deionised water (900 mL) and a paddle speed of 75 rpm.

Preferably, the modified release formulation has a biphasic profile *in vivo* with respect to amoxycillin, that is an initial burst from the immediate release phase to provide an acceptable C_{max} value, supplemented by a further contribution from the slow release phase, to extend the $T > MIC$ parameter to an acceptable value.

Preferably, the modified formulation provides an "Area Under the Curve" (AUC) value which is substantially similar to, for instance at least 80%, preferably at least 90%, more preferably about 100%, of that of the corresponding dosage of amoxycillin taken as a conventional (immediate release) formulation, over the same dosage period, thereby maximising the absorption of the amoxycillin component from the slow release component.

The pharmacokinetic profile for a dosage of the present invention may be readily determined from a single dosage bioavailability study in human volunteers. Plasma concentrations of amoxycillin may then be readily determined in blood samples taken from patients according to procedures well known and documented in the art.

Representative modified release formulations include a tablet, including swallow tablets, dispersible tablets, chewable tablets which may also be effervescent and/or dispersible and, a capsule, granules or a sachet, typically a swallow tablet.

Representative modified release formulations having an immediate and a
 5 slow release phase provide a unit dosage in the range 700 to 1300 mg, preferably, 950 to 1300 mg, more preferably 850 to 1250 mg, amoxycillin, for instance unit dosages of 1000, 875 and 750mg amoxycillin. Alternatively, and where the physical size of the dosage form is not a problem, the unit dosage may provide the whole dosage, for instance a single dosage sachet or dispersible tablet may comprise 1400
 10 to 2600 mg, preferably, 1900 to 2600 mg, amoxycillin, for instance unit dosages of 2000, 1750 and 1500mg amoxycillin. It will be appreciated that such 1000, 875 and 750mg formulations are novel.

Accordingly, in a further aspect, the present invention provides for a pharmaceutical formulation having an immediate release portion or phase and a slow
 15 release portion or phase comprising:

- (a) a unit dosage in the range 700 to 1300 mg, preferably, 950 to 1300 mg, amoxycillin, for instance unit dosages of 1000, 875 or 750 mg $\pm 5\%$ amoxycillin, or
- (b) a unit dosage in the range 1400 to 2600 mg, preferably 1700 to 2600 mg, more preferably 1900 to 2600 mg, amoxycillin, for instance unit dosages of 2000,
 20 1750 or 1500 mg $\pm 5\%$ amoxycillin ,

in combination with pharmaceutically acceptable excipients or carriers.

Preferably, the ratio of amoxycillin in the immediate and slow release phases is from 3:1 to 1:3, more preferably, from 2:1 to 2:3, yet more preferably 3:2 to 1:1. Representative ratios include about 2:1, 9:7 or 1:1. It is found useful to employ an
 25 excess of amoxycillin in the immediate release phase, to ensure an adequate C_{max} value.

In the modified release formulations of the present invention, the portion of amoxycillin which is released immediately may be provided as amoxycillin trihydrate or an alkaline salt thereof, for instance potassium or sodium amoxycillin,
 30 preferably, (crystallised) sodium amoxycillin or a mixture thereof, preferably amoxycillin trihydrate; while the portion of amoxycillin which is released slowly is provided as amoxycillin trihydrate or an alkaline salt thereof, for instance potassium or (crystallised) sodium amoxycillin or a mixture thereof, preferably (crystallised) sodium amoxycillin.

35 Preferably, the modified release formulation is a tablet. In a preferred modified release tablet comprising 1000 mg amoxycillin, the immediate release phase comprises about 563 mg $\pm 5\%$ amoxycillin trihydrate and the slow release

phase about 438 mg \pm 5% of amoxycillin, preferably as (crystallised) sodium amoxycillin.

5 In a representative modified release tablet of the present invention, the immediate release phase comprises about 438 mg amoxycillin, preferably amoxycillin trihydrate lanate and the slow release phase about 438 mg of amoxycillin, preferably (crystallised) sodium amoxycillin, providing overall an 875mg (14:1) tablet.

10 In a further representative tablet of the present invention, the immediate release phase comprises about 500 mg amoxycillin and the slow release phase about 250 mg of amoxycillin, preferably (crystallised) sodium amoxycillin, providing overall a 750mg (12:1) tablet.

It will be appreciated that the use of a mixture of amoxycillin trihydrate and sodium amoxycillin is more generally applicable to other pharmaceutical formulations comprising amoxycillin.

15 Accordingly, in a further aspect, the present invention provides for a pharmaceutical formulation comprising amoxycillin in which amoxycillin is provided as a mixture of amoxycillin trihydrate and sodium amoxycillin in a ratio of from 3:1 to 1:3, more preferably 7:3 to 1:3, yet more preferably from 2:1 to 2:3, most preferably 3:2 to 1:1. Preferably the formulation comprises more than 500 mg amoxycillin, more preferably at least 600 mg, most preferably at least 700 mg amoxycillin. Preferably, sodium amoxycillin is crystallised sodium amoxycillin. Representative formulation types include tablets, including immediate release and modified release tablets as herein described, as well as other solid dosage forms such as capsules, single dosage sachets and granules. Representative tablets include those comprising 1000, 875, 500 and 250 mg amoxycillin. Preferably, in modified release formulations of the present invention, the amoxycillin in the immediate release phase consists essentially of amoxycillin trihydrate and the amoxycillin of the slow release phase consists essentially of sodium amoxycillin.

25 For a tablet formulation, the immediate and slow release phases may be provided in a number of different formats.

In a preferred aspect, the immediate and slow release phases are provided as separate layers of a layered tablet.

35 Accordingly, in a further aspect, the present invention provides for a layered tablet comprising an immediate release layer comprising amoxycillin and a slow release layer comprising amoxycillin and a release retarding excipient which tablet: (a) is a bilayered tablet;

(b) comprises at least three layers, including an immediate release and a slow release layer, and comprising at least 275 mg of amoxycillin in the immediate release layer phase;

5 (c) comprises at least three layers, including an immediate release and a slow release layer, and in which the release retarding excipient in the slow release layer comprises xanthan gum and/or a pharmaceutically acceptable organic acid; or

(d) comprises at least three layers, including an immediate release and a slow release layer, and in which the amoxycillin is provided as a mixture of amoxycillin trihydrate and sodium amoxycillin, in a ratio of 3:1 to 1:3.

10 As used herein, the term "bilayer" tablet refers to a tablet consisting of an immediate release and a slow release layer, optionally with a coating layer.

An immediate release layer may be, for example, a layer which disintegrates immediately or rapidly and has a composition similar to that of known tablets which disintegrate immediately or rapidly. For example, the layer may comprise, in
15 addition to the active material content, excipients including diluents such as microcrystalline cellulose; disintegrants such as cross-linked polyvinylpyrrolidone (CLPVP), sodium starch glycollate; compression aids such as colloidal silicon dioxide and microcrystalline cellulose; and lubricants such as magnesium stearate. Such an immediate release layer may comprise around 60 to 85 % (all percentages
20 given herein are on a weight percentage basis unless otherwise stated), preferably 70 to 85 %, of active material content, around 10 to 30 %, preferably 10 to 20 % of fillers/compression aids, and conventional amounts of disintegrants and lubricants, typically about 0.5 to 3%, etc.

An alternative type of immediate release layer may be a swellable layer
25 having a composition which incorporates polymeric materials which swell immediately and extensively in contact with water or aqueous media, to form a water permeable but relatively large swollen mass. Active material content may be immediately leached out of this mass.

Slow release layers have a composition which comprises amoxycillin
30 together with a release retarding excipient which allows for slow release of amoxycillin. Suitable release retarding excipients include pH sensitive polymers, for instance polymers based upon methacrylic acid copolymers such as the Eudragit (trade mark) polymers, for example Eudragit L (trade mark) which may be used either alone or with a plasticiser; release-retarding polymers which have a high
35 degree of swelling in contact with water or aqueous media such as the stomach contents; polymeric materials which form a gel on contact with water or aqueous

media; and polymeric materials which have both swelling and gelling characteristics in contact with water or aqueous media.

Release retarding polymers which have a high degree of swelling include, *inter alia*, cross-linked sodium carboxymethylcellulose, cross-linked
5 hydroxypropylcellulose, high-molecular weight hydroxypropylmethylcellulose, carboxymethylamide, potassium methacrylatedivinylbenzene co-polymer, polymethylmethacrylate, cross-linked polyvinylpyrrolidone, high-molecular weight polyvinylalcohols etc.

Release retarding gellable polymers include methylcellulose,
10 carboxymethylcellulose, low-molecular weight hydroxypropylmethylcellulose, low-molecular weight polyvinylalcohols, polyoxyethyleneglycols, non-cross linked polyvinylpyrrolidone, xanthan gum etc.

Release retarding polymers simultaneously possessing swelling and gelling properties include medium-viscosity hydroxypropylmethylcellulose and medium-
15 viscosity polyvinylalcohols.

A preferred release-retarding polymer is xanthan gum, in particular a fine mesh grade of xanthan gum, preferably pharmaceutical grade xanthan gum, 200 mesh, for instance the product Xantural 75 (also known as Keltrol CR, Trade Mark, Monsanto, 800 N Lindbergh Blvd, St Louis, MO 63167, USA). Xanthan gum is a
20 polysaccharide which upon hydration forms a viscous gel layer around the tablet through which the active has to diffuse. It has been shown that the smaller the particle size, the slower the release rate. In addition, the rate of release of drug substance is dependent upon the amount of xanthan gum used and can be adjusted to give the desired profile. Controlled release formulations comprising from 7.5 to
25 25% xanthan gum are described in EP 0 234 670-A (Boots Co plc). The preferred embodiment is a tablet comprising ibuprofen as the drug substance and 15-20% xanthan gum, which is taken once daily.

Examples of other polymers which may be used include Methocel K4M (Trade Mark), Methocel E5 (Trade Mark), Methocel E50 (Trade Mark), Methocel
30 E4M (Trade Mark), Methocel K15M (Trade Mark) and Methocel K100M (Trade Mark). An example of a suitable polymer mixture is a mixture of Methocel E5 and K4M, for example 1:1, w:w.

Other known release-retarding polymers which may be incorporated include hydrocolloids such as natural or synthetic gums, cellulose derivatives other than
35 those listed above, carbohydrate-based substances such as acacia, gum tragacanth, locust bean gum, guar gum, agar, pectin, carageenin, soluble and insoluble alginates,

carboxypolymethylene, casein, zein, and the like, and proteinaceous substances such as gelatin.

Such a slow release layer may contain polymers which immediately swell in contact with water or aqueous media so that they form a relatively large swollen mass which is not immediately discharged from the stomach into the intestine.

The slow release layer may also include diluents such as lactose; compression aids such as microcrystalline cellulose; and lubricants such as magnesium stearate. The slow release layer may further comprise disintegrants, such as cross-linked polyvinylpyrrolidone (CLPVP) and sodium starch glycollate; binders such as povidone (polyvinylpyrrolidone); desiccants, such as silicon dioxide; and soluble excipients such as mannitol or other soluble sugars. Typically, the slow release layer comprises from about 60 to 80% by weight of amoxycillin; from 10 to 20 % by weight of diluent/compression aid and from 1 to 2.5 % by weight of lubricant.

When xanthan gum is used as the release-retarding polymer, the layer contains from 60 to 80% of amoxycillin, from 1 to 25%, preferably 2 to 15%, more preferably 4 to 15% of xanthan gum, from 10 to 30%, preferably 10 to 20% of fillers/compression aids, and conventional quantities of lubricants, all % being by weight of the layer. In a preferred embodiment, the slow release layer comprises from 70 to 80% of amoxycillin, from 4 to 10%, of xanthan gum, from 10 to 20% of microcrystalline cellulose, and from 1 to 2.5 % of magnesium stearate, all % being by weight of the layer.

When release-retarding polymers other than xanthan gum are used, the slow release layer may contain around 30 to 70%, preferably from 40 to 60%, of amoxycillin, from 15 to 45% of release-retarding polymer, from 0 to 30% of fillers/compression aids, conventional quantities of lubricants, and from 5 to 20% of soluble excipients, all % being by weight of the layer.

It has also been surprisingly found that when the amoxycillin in the slow release layer is in the form of a soluble salt thereof, such as sodium amoxycillin, then the release thereof may be retarded by the inclusion of an organic acid.

Accordingly, in a further aspect, the present invention provides for the use of a pharmaceutically acceptable organic acid as a release retarding excipient in a formulation comprising a pharmaceutically acceptable soluble salt of amoxycillin, for instance sodium or potassium amoxycillin, preferably sodium amoxycillin.

It will be appreciated that the use of an organic acid as a release retarding excipient is more generally applicable beyond the particular formulations hereinbefore described.

Accordingly, the present invention further provides for a pharmaceutical formulation comprising a pharmaceutically acceptable soluble salt of amoxycillin, for instance sodium amoxycillin, in a slow release phase which further comprises a release retarding excipient which is a pharmaceutically acceptable organic acid present in a molar ratio of from 100:1 to 1:10, preferably 50:1 to 1:5, more preferably 20:1 to 1:2 (amoxycillin to organic acid).

It is believed that intimate contact between the organic acid and the salt of amoxycillin in the pharmaceutical formulation, for instance as a consequence of compacted granule formation or direct compression in a tablet, causes some form of interaction which modifies the release of the amoxycillin component from the formulation.

Soluble pharmaceutically acceptable salts of amoxycillin include alkali metal salts such as sodium and potassium; alkaline earth metal salts such as magnesium and calcium, and acid salts such as amoxycillin hydrochloride. Preferably, the salt is sodium amoxycillin, more preferably crystallised sodium amoxycillin.

As used herein, the term "pharmaceutically acceptable organic acid" shall mean organic acids which are without pharmacological effect *per se*, have acceptable organoleptic properties, have acceptable density, do not have an extreme pH and are preferably solid. Examples thereof include mono-carboxylic acids and poly-carboxylic acids having from 2 to 25, preferably from 2 to 10, carbon atoms; monocyclic and polycyclic aryl acids such as benzoic acid; as well as monohydrogen, dihydrogen etc metal salts of multi-valent acids. A single pharmaceutically acceptable organic acid may be used, or two or more of such may be used in combination. Preferably, the organic acid is a C₍₂₋₁₀₎alkyl- or alkenyl-carboxylic acid having from one, two or three carboxylic acid groups, and optionally with one or more hydroxy substituents or an additional CO group in the carbon chain, for instance malonic acid, succinic acid, fumaric acid, maleic acid, adipic acid, lactic acid, levulinic acid, sorbic acid or a fruit acid such as tartaric acid, malic acid, ascorbic acid or citric acid, or an acidic salt thereof, more preferably anhydrous citric acid.

The organic acid may be used alone or in combination with a release retarding polymer as hereinbefore described. A preferred combination comprises citric acid and a release retarding gellable polymer, in particular xanthan gum. In the presence of the organic acid, for instance citric acid, xanthan gum may be used at a lower level than when included on its own, for instance, from 0.5 to 8%, preferably 1 to 5%, typically about 2%, by weight of the slow release layer.

When an organic acid is used as a release-retarding excipient, the slow release layer contains from 60 to 80% of a soluble salt of amoxycillin, from 10 to 30%, preferably 10 to 20% of fillers/compression aids, and conventional quantities of lubricants, all % being by weight of the layer. In a preferred embodiment, the
5 slow release layer comprises from 60 to 70 % of a soluble salt of amoxycillin, from 10 to 20% of microcrystalline cellulose, and from 1 to 2.5 % of magnesium stearate, all % being by weight of the layer.

In a representative example, a layered tablet comprises in the slow release layer crystallised sodium amoxycillin and citric acid, in a molar ratio of about 50:1
10 to 1:2, preferably 20:1 to 1:2, more preferably 2:1 to 1:1.2, yet more preferably about 1:1. In a preferred embodiment, the slow release layer comprises about 438 mg \pm 5% crystallised sodium amoxycillin, about 78 mg \pm 10% citric acid and about 2% by weight of xanthan gum.

In a preferred layered tablet comprising 1000 mg amoxycillin, the immediate
15 release layer comprises about 563 mg \pm 5% amoxycillin, preferably amoxycillin trihydrate, and the slow release layer about 438 mg \pm 5% of a soluble salt of amoxycillin, preferably crystallised sodium amoxycillin, about 78 mg \pm 10% citric acid and about 2% by weight of xanthan gum.

The tablet formulations of the invention may also include one or more barrier
20 layers, which may be located between the respective first and second layers, and/or on one or more of the outer surfaces of the first and second layers, for example the end faces of the layers of a substantially cylindrical tablet. Such barrier layers may, for example, be composed of polymers which are either substantially or completely impermeable to water or aqueous media, or are slowly erodable in water or aqueous
25 media or biological liquids and/or which swell in contact with water or aqueous media. Suitably the barrier layer should be such that it retains these characteristics at least until complete or substantially complete transfer of the active material content to the surrounding medium.

Suitable polymers for the barrier layer include acrylates, methacrylates,
30 copolymers of acrylic acid, celluloses and derivatives thereof such as ethylcelluloses, cellulose acetate propionate, polyethylenes and polyvinyl alcohols etc. Barrier layers comprising polymers which swell in contact with water or aqueous media may swell to such an extent that the swollen layer forms a relatively large swollen mass, the size of which delays its immediate discharge from the stomach into the intestine.
35 The barrier layer may itself contain active material content, for example the barrier layer may be a slow or delayed release layer. Barrier layers may typically have an individual thickness of 2 mm to 10 microns.

Suitable polymers for barrier layers which are relatively impermeable to water include the Methocel (trade mark) series of polymers mentioned above, for example Methocel K100M, Methocel K15M, Methocel E5 and Methocel E50, used singly or combined, or optionally combined with an Ethocel (trade mark) polymer.

5 Such polymers may suitably be used in combination with a plasticiser such as hydrogenated castor oil. The barrier layer may also include conventional binders, fillers, lubricants and compression acids etc such as Polyvidon K30 (trade mark), magnesium stearate, and silicon dioxide, e.g. Syloid 244 (trade mark).

10 The tablet formulation of the invention may be wholly or partly covered by a coating layer, which may be a protective layer to prevent ingress of moisture or damage to the tablet. The coating layer may itself contain active material content, and may, for example, be an immediate release layer, which immediately disintegrates in contact with water or aqueous media to release its active material content, for example amoxycillin and potassium clavulanate. Preferred coating
15 materials comprise hydroxypropylmethylcellulose and polyethylene glycol, with titanium dioxide as an opacifying agent, for instance as described in WO 95/28927 (SmithKline Beecham).

As well as active material content etc, the tablet of the invention may also include a pH modifying agent, such as a pH buffer, which may be contained in either
20 the immediate-, or slow-release layers, or in a coating around all or part of the tablet. A suitable buffer is calcium hydrogen phosphate.

In a tablet without a barrier layer, the immediate release layer comprises from 50 to 60% and the slow release layer comprises from 40 to 50% of the overall tablet weight. When a barrier layer is present, the immediate release layer typically
25 comprises from 40 to 50%, the slow release layer comprises from 35 to 45%, and the barrier layer comprises from 5 to 20% of the overall tablet weight.

It is found that a satisfactory pharmacokinetic profile may be obtained from a bilayered tablet of the present invention without the need to include a barrier layer. Accordingly, a bi-layer tablet is preferred. This also reduces the complexity of the
30 manufacturing process.

It will be appreciated that 1000, 875 and 750 mg layered tablets having an immediate release layer and a slow release layer are novel. Accordingly, in a further aspect, the present invention provides for a pharmaceutical layered tablet formulation comprising an immediate release layer and a slow release layer and
35 comprising from 700 to 1250 mg amoxycillin, preferably 1000, 875 or 750 mg \pm 5% amoxycillin, in combination with pharmaceutically acceptable excipients or carriers. Preferably, the layered tablet is a bi-layered tablet.

Suitably the tablet formulations of the invention may be formed by known compression tableting techniques, for example using a known multi-layer tableting press. Preferably, in a preliminary step, slugging or roller compaction is used to form granulates. Lubricants and compression aids (if used) are then added, to form a
5 compression blend for subsequent compaction.

Preferred bilayer tablets of the present invention may be made by a process which comprises as, an early phase, the formation of slow release compacted granules, comprising the steps of blending together sodium amoxycillin, a
10 diluent/compression aid such as microcrystalline cellulose, a portion of the lubricant (between 40 and 60 %, typically about 50%) and a pharmaceutically acceptable organic acid such as a fruit acid, for instance citric acid, or a release retarding polymer such as xanthan gum or a mixture thereof, compacting the blend, for instance in a roller compactor or by slugging, and then milling, to form slow release granules. Preferably such granules have a size in the range 100 to 1000 microns.
15 The incorporation of xanthan gum appears to also have an unexpected benefit on processibility.

Such slow release compacted granules may then be blended with other excipients such as magnesium stearate, to form a slow release compression blend.

In addition, amoxycillin trihydrate, microcrystalline cellulose, a disintegrant
20 such as sodium starch glycollate and a lubricant such as magnesium stearate, are blended together, compacted, for instance in a roller compactor or by slugging, and then milled to form immediate release compacted granules. These immediate release compacted granules may then be blended with other excipients such as magnesium stearate and colloidal silica, to form an immediate release compression
25 blend.

The immediate release and slow release compression blends may then be compressed as separate layers on a bilayer tablet press, to form bilayer tablets.

Such slow release granules are novel. Accordingly, in a further aspect, the present invention provides for compacted granules comprising a soluble salt of
30 amoxycillin, for instance sodium amoxycillin, a diluent/compression aid, and an organic acid or a release retarding polymer or a mixture thereof, as hereinbefore defined. In a yet further aspect, the present invention also provides for compacted granules comprising amoxycillin trihydrate, a diluent/compression aid, and a release retarding polymer, as hereinbefore defined.

35 Alternatively, a dry densification process may be used, e.g. briquetting. Typically the active material content, pH modifiers, buffers, fillers and/or diluent, release retarding agents, disintegrants and binders, when used are mixed, then

lubricants and compression aids are added. The complete mixture may then be compressed under high pressure in the tablet press. A wet granulation process may be also be used, for instance with isopropanol as the solvent and Polyvidon K-30 (trade mark) as the wet granulating aid.

5 A barrier layer, if present, may typically be made up by a wet granulation technique, or by dry granulation techniques such as roller compaction. Typically the barrier material, e.g. Methocel (trade mark) is suspended in a solvent such as ethanol containing a granulation acid such as Ethocel or Polyvidon K-30 (trade mark), followed by mixing, sieving and granulation. Typically a first layer may be formed, 10 then a barrier layer deposited upon it, e.g. by compression, spraying or immersion techniques, then the second layer may be formed so that the barrier layer is sandwiched between the first and second layers. Additionally, or alternatively, the first and second layers may be formed and a barrier layer may then be formed, for instance by compression, spraying or immersion, on one or more of the end faces of 15 the tablet.

Tablet cores may then be coated with a coating layer which may be applied from an aqueous or an organic solvent system, preferably an aqueous solvent system, to provide film coated tablets.

20 The invention also provides a method for the manufacture of a tablet formulation as described above comprising the steps of forming said first and second layers, and any barrier layers and coating layer(s) which may be present.

 In addition to the layered tablet approach hereinbefore described, other types of tablet may be used to provide an immediate release phase and a slow release phase, using the excipients hereinbefore described but providing the phases in 25 different formats. Thus, the slow release phase may form the core of a tablet which is then surrounded by an outer casing forming the immediate release phase, optionally with an intermediate coating layer around the core and/or a final coating layer around the outer casing (see WO 95/28148, SmithKline Beecham). The slow release phase may also be provided as granules which are dispersed in a matrix of 30 amoxycillin, the matrix forming the immediate release phase (see WO 96/04908, SmithKline Beecham).

 In a further variant, a monolith modified release tablet may be prepared from slow release compacted granules comprising amoxycillin, a diluent/compression aid such as microcrystalline cellulose, and a pharmaceutically acceptable organic acid 35 such as a fruit acid, for instance citric acid (if amoxycillin is present as a soluble salt thereof), or a release retarding polymer such as xanthan gum or a mixture thereof, preferably a release retarding polymer (as hereinbefore described); and immediate

release compacted granules comprising amoxycillin (as hereinbefore described) the granules being combined with extragranular excipients to form tablets. Such granules may also be processed into other pharmaceutical formulations, for instance single dosage sachets, capsules or chewable tablets comprising a unit dosage as
5 hereinbefore described.

Chewable tablets according to the present invention typically comprise a chewable base formed from, for instance, mannitol, sorbitol, dextrose, fructose or lactose alone or in combination. A chewable tablet may also comprise further excipients, for instance, disintegrants, lubricants, sweetening agents, colouring and
10 flavouring agents. Such further excipients together will preferably comprise from 3 to 10%, more preferably 4 to 8%, yet more preferably 4 to 7% by weight of the tablet. Disintegrants may be present in from 1 to 4%, preferably from 1 to 3%, more preferably from 1 to 2% by weight of the tablet. Representative disintegrants include crospovidone, sodium starch glycollate, starches such as maize starch and
15 rice strach, croscarmellose sodium and cellulose products such as microcrystalline cellulose, microfine cellulose, low substituted hydroxy propyl cellulose, either used singly or in admixture. Preferably, the disintegrant is crospovidone. Lubricants may be present in from 0.25 to 2.0%, preferably from 0.5 to 1.2% by weight of the tablet. Preferred lubricants include magnesium stearate. Preferably, the sweetening agent is
20 an artificial sweetening agent such as sodium saccharin or aspartame, preferably aspartame, which may be present in from 0.5 to 1.5% by weight of the tablet. Preferably, a tablet of the present invention is substantially free of sugar (sucrose). Preferred flavouring agents include fruit flavours which may be natural or synthetic, for instance peppermint, cherry and banana, or a mixture thereof.

25 Single dose sachets according to the present invention comprise, in addition to the drug substance, excipients typically included in a sachet formulation, such as a sweetener, for instance aspartame, flavourings, for instance fruit flavours, as well as silica gel, to act as a desiccant.

Capsules according to the present invention comprise, in addition to the drug
30 substance, excipients typically included in a capsule, for instance starch, lactose, microcrystalline cellulose, magnesium stearate.. Preferably, capsules are prepared from materials such as HPMC or gelatin/PEG combination.

A process for the preparation of crystallised sodium amoxycillin is described in EP-A-0 131 147 (Beecham Group plc).

35 In a further embodiment, the slow release phase may be provided as a separate component, for instance as a separate tablet, so that the unit dosage is provided as a combination of a conventional component in which amoxycillin is

released immediately, and a further formulation, for instance a tablet, comprising amoxycillin from which amoxycillin is released slowly. The combined weights of amoxycillin in the conventional and slow release formulations will provide the overall unit dosage. Thus, for instance a dosage of 2000mg may be provided by a
5 combination of two existing 500mg amoxycillin tablets in combination with a slow release tablet comprising 1000 mg of amoxycillin. Furthermore, a dosage of 1750mg may be provided by an existing 875mg tablet (SmithKline Beecham) in combination with a slow release tablet comprising 875 mg of amoxycillin. In addition, a dosage of 1500mg may be provided by two existing 500mg tablets of
10 amoxycillin in combination with a slow release tablet comprising 500 mg of amoxycillin. Accordingly, in a further aspect, the present invention provides for a kit comprising a conventional (immediate release) tablet comprising amoxycillin, and a slow release tablet comprising amoxycillin.

In a further aspect, the present invention provides for a slow release
15 pharmaceutical formulation, preferably a tablet, comprising amoxycillin (as the sole active ingredient) formulated with a release retarding excipient which causes a slow release of the amoxycillin from the formulation, and excluding; tablets which comprise 750mg or less of amoxycillin in which the amoxycillin is present essentially as amoxycillin trihydrate; or tablets comprising from 400 to 500mg
20 amoxycillin in which amoxycillin is present as a mixture comprising at least 70% amoxycillin trihydrate and up to 30% sodium amoxycillin in combination with hydroxypropyl methylcellulose as a release retarding excipient.

Such formulations may comprise from 100 to 1250mg amoxycillin which may be amoxycillin trihydrate or (crystallised) sodium amoxycillin or a mixture
25 thereof, for instance 500, 875 or 1000mg amoxycillin. Suitable excipients for slow release are those hereinbefore described for slow release layers. The formulation may comprise from 1 to 25%, preferably from 2 to 15%, more preferably 4 to 10% of xanthan gum, or from 10 to 25, preferably 15 to 20% of a hydroxypropylmethylcellulose, for instance Methocel K100LV or Methocel K4M.
30 Alternatively, such formulations may comprise citric acid, optionally with xanthan gum, as hereinbefore described.

Preferably, the unit dosage forms of the present invention are packaged in containers that inhibit the ingress of atmospheric moisture, for instance blister packs, tightly closed bottles or desiccated pouch packs etc which are conventional in the art.
35 Preferably, bottles also include a desiccating material, to preserve the clavulanate. Preferred bottles include HDPE bottles. Preferred blister packs include cold-formed blister packs in which each blister may contain one tablet, or two tablets, where the

unit dosage is two tablets, for instance 2 x 1000/62.5mg tablets, to improve patient compliance.

It will be appreciated that the present application relates to inventions in which the drug substance consists essentially of amoxycillin and does not extend
5 inventions in which the drug substance is amoxycillin in combination with potassium clavulanate.

The invention will now be described by way of example only with reference to the accompanying drawings, in which:

Fig. 1 shows the structure of various types of layered tablets of the present
10 invention, in particular the structure of substantially cylindrical compressed tablets are shown in longitudinal section. In Fig 1A, the tablet comprises a first layer (1) and a second layer (2), without any barrier layer or coating layer. In Fig 1B, the tablet comprises a first layer (1), a second layer (2), and a barrier layer (3) sandwiched between the first and second layers (1) and (2). In Fig 1C, the tablet
15 comprises a first layer (1), a second layer (2), and a barrier layer (3) located on the end face of the second layer (2). In Fig 1D, the tablet comprises a first layer (1), a second layer (2), a barrier layer (3) sandwiched between the first and second layers (1) and (2), and a coating layer (4) which partly covers the tablet. The dotted line shows the possibility of the coating layer (4A) covering the entire tablet. In Fig. 1E,
20 the tablet comprises a first layer (1) a second layer (2), and a third layer (3) intermediate between the first and second layers (1) and (2). All three of these layers (1), (2) and (3) include active material content.

All publications and references, including but not limited to patents and
25 patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and
30 references.

Example 1 – 1000 mg modified release tablet

Name of Ingredient	mg/tablet	% w/w
Immediate Release Layer		
Amoxycillin Trihydrate	654.1*	40.88
Microcrystalline Cellulose	216.6	13.28
Sodium Starch Glycollate	18.0	1.12
Colloidal Silicon Dioxide	6.3	0.39
Magnesium Stearate	9.0	0.56
Total (Immediate Release Layer)	900.0	56.23
Slow Release Layer		
Sodium Amoxycillin	480.8**	30.05
Microcrystalline Cellulose	113.2	7.08
Xanthan Gum	14.0	0.87
Citric Acid (anhydrous)	78.0	4.87
Colloidal Silicon Dioxide	1.5	0.09
Magnesium Stearate	14.0	0.87
Total (Sustained Release Layer)	700.0	43.74
Film coat – Opadry YS-1-7700		
Composition		
Hydroxypropylmethylcellulose 2910 6cp	11.6	
Hydroxypropylmethylcellulose 2910 15cp	3.9	
Titanium dioxide	15.1	
Polyethylene Glycol 3350	2.3	
Polyethylene Glycol 8000	2.3	
Total weight of coated tablet	1635.2	

* Equivalent to 562.5 mg of amoxycillin based on an assay of 86.0%

**Equivalent to 437.5 mg amoxycillin based on an assay of 91.0%

5

Example 2 – 1000/62.5 mg modified release tablet The immediate release layer and film coat are as for the tablet of Example 1

Name of Ingredient	mg/tablet	% w/w
Slow Release Layer		
Sodium Amoxycillin	480.8**	30.05
Microcrystalline Cellulose	127.2	7.95
Citric Acid (anhydrous)	78.0	4.87
Colloidal Silicon Dioxide	1.5	0.09
Magnesium Stearate	14.0	0.87
Total (Slow Release Layer)	700.0	43.74
Total Weight of coated tablet	1635.2	

**Equivalent to 437.5 mg amoxycillin based on an assay of 91.0%

10

Preparation of modified release tablets

Amoxycillin trihydrate and microcrystalline cellulose (about 90% of the total) were milled and screened and then blended with magnesium stearate. This blend was roller compacted, using a Chilsonator, and milled to form immediate release granules. The remaining magnesium stearate and microcrystalline cellulose, sodium starch glycolate and colloidal silicon dioxide were then milled and screened and added to these granules and blended to form the immediate release compression blend.

Crystallised sodium amoxycillin microcrystalline cellulose (about 70% of the total) and anhydrous citric acid were milled and blended with xanthan gum (if applicable), magnesium stearate (about 70% of the total) and colloidal silicon dioxide. This blend was then roller compacted in a Chilsonator, and milled to form slow release granules. The remaining magnesium stearate and microcrystalline cellulose were added to these granules and blended to form the slow release compression blend.

The two blends were then compressed as separate layers in a bilayer tablet press equipped with punches measuring 0.0406 inches by 0.8730 inches and having a modified capsule shape.

Finally, the tablet cores were coated with an aqueous film coating, using a 15% solids aqueous suspension, in a 60 inch coating equipped with 4 spray guns..

Example 3 - Slow release tablet (875 mg)**(a) Sodium Amoxycillin Tablet**

	mg/tablet	%
Crystallised Sodium Amoxycillin 91%*	961.54	73.96
Dried Microcrystalline Cellulose	273.46	21.04
Magnesium Stearate	13.0	1.00
Xanthan gum 200 mesh**	52.0	4.00
Total	1300	100

(b) Sodium Amoxycillin Tablet with citric acid

	mg/tablet	%
Crystallised Sodium Amoxycillin 91%*	961.54	66.31
Dried Microcrystalline Cellulose	288.96	19.92
Magnesium Stearate	14.50	1.00
Citric acid (anhydrous)	156	10.75
Xanthan gum 200 mesh**	29.0	2.00
Total	1450	100

(c) Amoxycillin Trihydrate Tablet

	mg/tablet	%
Amoxycillin Trihydrate 86%*	1017.4	78.26
Dried Microcrystalline Cellulose	217.6	16.74
Magnesium Stearate	13.0	1.00
Xanthan Gum, 200 mesh**	52.0	4.00
Total	1300	100

* adjusted for the potency of the amoxycillin component and corresponding to 875 mg amoxycillin,

5 ** Xantural 75

Example 4 – 875mg modified release tablet**Slow release layer**

- 10 This may be formed using half the quantities given above, for a slow release layer comprising about 438 mg amoxycillin.

Immediate release layer – 1

	Amoxycillin trihydrate	507 mg
15	(equiv to amoxycillin free acid)	(438)
	Microcrystalline cellulose (Avicel PH102)	196.8
	Sodium starch glycollate (Explotab)	26
	Magnesium stearate	6.5

20 Immediate release layer - 2

	Amoxycillin trihydrate	507mg
	(equiv to amoxycillin free acid)	(438)
	Microcrystalline cellulose (Avicel PH102)	206
	Sodium starch glycollate (Explotab)	34
25	Talc	67
	Magnesium stearate	25
	Silica (Syloid)	17

Barrier Layers

- 30 Barrier layers and methods for their preparation are described in WO 95/20946 (SmithKline Beecham).

Preparation of Tablets

The active ingredients, fillers and diluents (microcrystalline cellulose), release controlling agents (if present), disintegrants (crospovidone, sodium starch glycollate) etc are mixed. Lubricants (talc, Mg-stearate) and colloidal silicon dioxide (Syloid 244) are added, and mixing is continued for another minute. The complete mixture is slugged on a tablet press or roller compacted (briquetting step), followed by size reduction (Apex, Fitzmill, Frewitt) and passage through an oscillatory sieve or particle size classifier (Kason, Sweco). If the flow properties are unsatisfactory, the briquetting step is repeated. Separate compressed blends are prepared for the immediate and slow release layers, and barrier layer, if present.

In some cases, where the bulk density is rather low, a densifying step (pre-tabletting and sieving as in the briquetting method) may be required in order to achieve the nominal weight of a particular layer.

The blends are then compressed as separate layers on a layer tablet press to form bilayered tablets. Tablets may then be coated with a white opaque coating, for instance the product Opadry, Opaspray (Colorcon).

Example 5 - Dissolution Testing Methods

The release of amoxycillin from tablets into static media was measured using the <711> Dissolution Test, Apparatus 2, provided in USP 23, 1995.

Test specifications:

Temperature:	37.0 ± 0.5°C
Medium:	Deionized water, 900 mL
Paddle speed	75 rpm

Method

Aliquots of medium were removed for assay after 15, 30, 45, 60, 90, 120, 150, 180, 240, 300 360, 420 and 480 min, each aliquot being replaced simultaneously by an equal volume of medium to maintain constant volume. The amount of drug substance was determined by UV spectrometry, at 272nm. The resulting dissolution profile for the tablets of Example 1 and 2 are shown as Fig 2.

in vivo Pharmacokinetic evaluation of formulations

The bioavailability of dosages comprising amoxycillin and potassium clavulante were evaluated in two human volunteer studies, Study A and Study B. It was not

anticipated that the presence of potassium clavulanate would affect the performance of the amoxycillin component.

The two studies were open, randomised, crossover studies in healthy volunteers.

- 5 Each dosage was administered with the aid of approximately 200 mL water, at the start of a light breakfast and after an overnight fast. Blood samples were collected into tubes containing EDTA at nominal times of pre-dose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10 and 12 h after start of dosing, for assay of plasma levels of amoxycillin and clavulanate. Samples were cooled in an ice-bath awaiting further processing.
- 10 Plasma was separated by refrigerated centrifugation at 4°C and transferred to appropriately labelled polypropylene specimen containers and stored frozen at approximately -70°C until assayed.

- Samples were assayed for amoxycillin using a method based on protein precipitation with acetonitrile. Amoxycillin was extracted from human plasma (50 µL) by means of protein precipitation, using acetonitrile containing the internal standard and quantified by LC/MS/MS. Specifically, human plasma (50 µL) was pipetted into a 1.5 mL Eppendorf tube followed by the addition of acetonitrile containing the internal standard ([¹³C₆]-amoxycillin, 200 µL). The tube was capped, vortex mixed
- 20 and shaken for approximately 15 minutes. After centrifuging the sample (approximately 11,000 x g, for 15 minutes), the supernatant was transferred to a silanised 1.1 mL tapered autosampler vial containing 200 µL of 5mM ammonium acetate solution. An aliquot of extract was injected onto the HPLC/MS/MS system for analysis. The mass spectrometer was operated in positive ion mode, employing a
- 25 Turbo IonSpray interface. Multiple reaction monitoring (MRM) was used to detect the components, amoxycillin and [¹³C₆]-amoxycillin. The MRM procedure involves (1) mass selection of a characteristic ion of the required drug or internal standard in the first quadrupole mass analyser (2) fragmentation of the selected ion in the instrument's collision cell (3) detection of a fragment ion which is
- 30 characteristic of the compound of interest. Quantification is performed by comparison of the chromatographic peak areas of the drug relative to the area of the internal standard. Linear responses in the analyte/internal standard peak area ratios were observed for analyte concentrations ranging from 0.05 µg/mL (lower limit of quantification; LLQ) to 10 µg/mL (upper limit of quantitation: ULQ).

35

QC samples were assayed with each batch of samples against separately prepared calibration standards. The results of the QC samples were used to assess the day-to-day performance of the assay.

- 5 Plasma concentration-time data for each subject in each regimen were analysed by non-compartmental methods using the non-compartmental pharmacokinetic analysis program WinNonlin Professional Version 1.5. All calculations were based on actual sampling times. Pharmacokinetic parameters determined included maximum observed plasma concentration (C_{max}) and time to reach maximum plasma concentration (T_{max}). The apparent terminal elimination rate constant (λ_z) was derived from the log-linear disposition phase of the concentration-time curve using linear least-squares regression with visual inspection of the data to determine the appropriate number of points to calculate λ_z . The apparent terminal elimination half-life ($T_{1/2}$) was calculated as $\ln(2)/\lambda_z$.
- 15 Area under the plasma concentration-time curve from time zero to the last quantifiable plasma concentration [$AUC(0-t)$] was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid [Chiou WL., J. Pharmacokinet. Biopharm., 1978, 6, 539-547].
- 20 The area under the plasma concentration-time curve extrapolated to infinity [$AUC(0-\infty)$] was calculated as the sum of $AUC(0-t)$ and $C(t)/\lambda_z$, where $C(t)$ was the predicted concentration from the log-linear regression analysis at the last measurable time point.
- 25 The time above the minimum inhibitory plasma concentration ($T > MIC$) was calculated manually by graphical interpolation, where the minimum inhibitory plasma concentrations was defined as 4 ug/mL for amoxycillin.

- 30 The mean concentration-time profiles for amoxycillin was derived at each nominal sampling time for each formulation. In cases where a post-dose value was not quantifiable, a value of 1/2 the LLQ (0.050 ug/mL) was assigned to determine the mean value. Where the calculated mean value was less than the LLQ or was based on greater than 50% NQ values, a value of NQ was assigned for that sampling time.

- 35 Log_e-transformed C_{max} and untransformed $T > MIC$ for each of the formulations were analysed using Analysis of Covariance (ANCOVA) fitting a single term for formulation and fitting the data from the reference formulation as a co-variate. The

95% confidence intervals for the means of each formulation were constructed using the residual variance from the model. For C_{max}, the confidence interval estimates on the log scale were then back-transformed to obtain the 95% confidence intervals of the geometric mean. These results were displayed graphically.

- 5 Assumptions underlying the analyses were assessed by inspection of residual plots. Homogeneity of variance was assessed by plotting the studentised residuals against the predicted values from the model, while normality was assessed using normal probability plots. Particular attention was paid to any outlying values observed with the reference formulation.

10 Study A

The first study compared three modified release dosages of 1750/125 mg (formulations I to III) and a fourth modified release dosages of 1500/125 mg (formulation IV) against an immediate release dosage of 1750/125 mg (formulation V), as follows:

- 15 (a) a dosage of 1750/125 mg amoxycillin/potassium clavulanate, made up of a combination of one modified release tablet comprising 875/125 mg amoxycillin trihydrate/clavulanate and 4% xanthan gum and one immediate release tablet comprising 875 mg amoxycillin trihydrate (formulation I);
- 20 (b) a dosage of 1750/125 mg amoxycillin/potassium clavulanate, made up of a combination of one modified release tablet comprising 875/125 mg crystallised sodium amoxycillin/clavulanate and 4% xanthan gum and one immediate release tablet comprising 875 mg amoxycillin trihydrate (formulation II);
- 25 (c) a dosage of 1750/125 mg amoxycillin/potassium clavulanate, made up of a combination of one modified release tablet comprising 875/125 mg crystallised sodium amoxycillin/clavulanate, citric acid (156 mg) and 2% xanthan gum and one immediate release tablet comprising 875 mg amoxycillin trihydrate (formulation III);
- 30 (d) a dosage of 1500/125 mg amoxycillin/potassium clavulanate (made up of a modified release tablet comprising 500/125 mg crystallised sodium amoxycillin/potassium clavulanate and two immediate release tablet comprising 500 mg amoxycillin trihydrate (Amoxyl, SmithKline Beecham) (formulation IV); and
- 35 (e) a dosage of 1750/125 mg amoxycillin/potassium clavulanate, made up of a combination of one immediate release tablet comprising 875/125 mg amoxycillin trihydrate/clavulanate (Augmentin, SmithKline Beecham) and one immediate release tablet comprising 875 mg amoxycillin trihydrate (Amoxyl, SmithKline Beecham) (formulation V).

Results

Formulation	n	C _{max} ¹	T>MIC ^{1,2}	AUC ^{1,3}
I	8	12.75 (4.96)	4.5 (1.8)	47.83
II	8	18.56 (4.72)	4.4 (1.0)	57.46
III	8	13.03 (2.34)	5.73 (2.54)	54.93
IV	8	17.33 (4.66)	4.8 (0.9)	56.71
V	40	20.21 (6.09)	4.2 (0.9)	56.33

() standard deviation

5 ¹ arithmetic mean value

² T>MIC is the time (h) above an amoxycillin concentration of 4 µg/ml

³ Area under the curve (0 to 12 h, µg.h/mL)

The pharmacokinetic profile is shown in Figure 3.

10

Study B

The second study investigated two different modified release dosages of 2000/125 mg (formulations VI and VII) against an immediate release dosage of 2000/125 mg (formulation VIII), as follows:

- 15 (a) a dosage of 2000/125 mg amoxycillin/potassium clavulanate, made up of two bilayer tablets according to Example 1 (formulation VI);
- (b) a dosage of 2000/125 mg amoxycillin/potassium clavulanate, made up of two bilayer tablets according to Example 2 (formulation VII);
- 20 (c) a dosage of 2000/125 mg amoxycillin/potassium clavulanate, made up of a combination of three tablets each comprising 500 mg amoxycillin (Amoxyl, SmithKline Beecham) and one tablet comprising 500 mg amoxycillin and 125 mg potassium clavulanate (Augmentin, SmithKline Beecham) (formulation VIII).

Results

Formulation	N	C _{max} ¹	T>MIC ^{1,2}	T>MIC ^{1,3}	AUC ^{1,4}
VI	7	17.41 (1.93)	6.0 (1.3)	4.8 (1.2)	74.9
VII	8	17.46 (6.02)	5.9 (1.3)	4.0 (1.3)	71.5
VIII	12	23.75 (5.73)	4.9 (1.1)	3.5 (1.0)	69.2

() standard deviation

5 ¹ arithmetic mean value

² T>MIC is the time (h) above an amoxycillin concentration of 4 µg/ml

³ T>MIC is the time (h) above an amoxycillin concentration of 8 µg/ml

⁴ Area under the curve (0 to 12 h, µg.h/mL).

10 Comparison of the AUC values for formulations VI and VII (bilayer tablets) against
VIII (immediate release tablets) shows that the absorption of the amoxycillin
component has not been compromised by formulating a part of it in a slow release
layer. This means that there is no extra, unabsorbed amoxycillin which may
15 otherwise cause problems further down in the GI tract, for instance due to a lack of
absorption and destruction of symbiotic bacteria

It was also found that for formulation VI, there was less inter-subject variability in
the amoxycillin plasma concentrations than for formulation VII. These formulations
were the same, except that formulation VI also comprised xanthan gum (2%) in the
20 slow release layer.

The pharmacokinetic profile for amoxycillin plasma concentration is shown in
Figure 4 (in which A is formulation VI, B is formulation VII, D is formulation VIII).

25 The present invention also extends to formulations which are bioequivalent to the
tablets of formulations VI and VII, in terms of both rate and extent of absorption, for
instance as defined by the US Food and Drug Administration and discussed in the
so-called "Orange Book" (Approved Drug Products with Therapeutic Equivalence
Evaluations, US Dept of Health and Human Services, 19th edn, 1999).

30

Reference Data

5 The existing Augmentin 875/125mg tablet has a C_{\max} value of $11.6 \pm 2.8 \mu\text{g/ml}$ (Physicians Desk Reference, Medical Economics Co, 52 edition, 1998, 2802). The time above MIC was about 40% of the 12 hour dosing interval for an MIC of $2 \mu\text{g/ml}$ and about 30% for an MIC of $4 \mu\text{g/ml}$ (SmithKline Beecham data).